Duration of benefits differs between methods : IV glutathione provides immediate peak plasma concentrations but benefits typically fade within 6 months of discontinuation, while oral supplementation offers sustained effects with regular daily dosing
GLP-1RA therapy has shown potential benefits in reducing the risk of major adverse cardiovascular events and improving kidney outcomes in patients with diabetes at high risk for cardiovascular disease
The Primary Care Companion For CNS Disorders , 27 (3)
It's best to consult with your physician if you suspect a deficiency
However, and despite these limitations, SGLT-2 inhibitors or a GLP-1RA with proven CV disease benefit are recommended in patients with type 2 diabetes and CV disease, established kidney disease, or HF [7,8,9,10]
Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism